Matches in Wikidata for { <http://www.wikidata.org/entity/Q37376149> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- Q37376149 description "article científic" @default.
- Q37376149 description "article scientifique" @default.
- Q37376149 description "articolo scientifico" @default.
- Q37376149 description "artigo científico" @default.
- Q37376149 description "artículu científicu espublizáu en 2009" @default.
- Q37376149 description "bilimsel makale" @default.
- Q37376149 description "scientific article published on 23 January 2009" @default.
- Q37376149 description "vedecký článok" @default.
- Q37376149 description "vetenskaplig artikel" @default.
- Q37376149 description "videnskabelig artikel" @default.
- Q37376149 description "vědecký článek" @default.
- Q37376149 description "wetenschappelijk artikel" @default.
- Q37376149 description "wissenschaftlicher Artikel" @default.
- Q37376149 description "наукова стаття, опублікована в січні 2009" @default.
- Q37376149 description "научни чланак" @default.
- Q37376149 description "مقالة علمية نشرت في 23 يناير 2009" @default.
- Q37376149 name "Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy" @default.
- Q37376149 name "Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy" @default.
- Q37376149 name "Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy" @default.
- Q37376149 type Item @default.
- Q37376149 label "Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy" @default.
- Q37376149 label "Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy" @default.
- Q37376149 label "Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy" @default.
- Q37376149 prefLabel "Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy" @default.
- Q37376149 prefLabel "Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy" @default.
- Q37376149 prefLabel "Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy" @default.
- Q37376149 P1433 Q37376149-CCF31E33-B057-47AB-8F1E-633669419968 @default.
- Q37376149 P1476 Q37376149-D3D926A2-99A1-4CF9-AABF-2BFA50FFDDEE @default.
- Q37376149 P2093 Q37376149-A717F1B1-69FD-4798-8154-38BA5E68D36B @default.
- Q37376149 P2860 Q37376149-030A3A02-EEB1-4A7D-B008-4FA1E44D66C5 @default.
- Q37376149 P2860 Q37376149-069638C9-FD6F-45FE-A89D-6C0582BED655 @default.
- Q37376149 P2860 Q37376149-2123D37F-80DD-4B51-92E9-7CDEA3B05960 @default.
- Q37376149 P2860 Q37376149-38FD1DF4-54E7-44A6-A542-7CA34364F009 @default.
- Q37376149 P2860 Q37376149-5637F13F-8781-40C2-B934-EEAFA8CEA5D0 @default.
- Q37376149 P2860 Q37376149-6F585FFF-B860-474A-8293-BE374BD9C2D0 @default.
- Q37376149 P2860 Q37376149-728D3E65-508E-4578-A8B8-72F3456CAFB2 @default.
- Q37376149 P2860 Q37376149-A26C3F92-10A2-4003-A534-FC08F58C80C4 @default.
- Q37376149 P2860 Q37376149-BED9C949-370A-40D9-9E99-E38B5CAD0C1B @default.
- Q37376149 P2860 Q37376149-BEDDB03F-77B1-4A07-BC71-03432E5B0361 @default.
- Q37376149 P2860 Q37376149-CCB6EA9F-ACEC-494E-A31A-C36138F4A979 @default.
- Q37376149 P2860 Q37376149-E6025D9F-31F6-49A3-AB77-E99B58C0D38B @default.
- Q37376149 P2860 Q37376149-F109FC6A-1882-4A04-A11F-3FD8E673D522 @default.
- Q37376149 P2888 Q37376149-4E9160B5-FDD8-4D33-977A-E6B4C176C32F @default.
- Q37376149 P304 Q37376149-0B24EC27-359D-4079-A8A5-5394860D3960 @default.
- Q37376149 P31 Q37376149-0d8a0827-5a24-4aba-96ae-852be358027e @default.
- Q37376149 P31 Q37376149-57BD80AF-E872-4074-9A51-5DCA82806B6F @default.
- Q37376149 P356 Q37376149-6092D070-A004-49BB-B82D-6FD5EAC3B540 @default.
- Q37376149 P478 Q37376149-C3995BC7-A6EE-4C6A-9D68-7F528E5DCBF2 @default.
- Q37376149 P577 Q37376149-C62236B8-28AF-4993-8DFF-5F5D4A38ED3B @default.
- Q37376149 P698 Q37376149-33CE70FA-A214-4498-81EE-588B41546B22 @default.
- Q37376149 P921 Q37376149-5E1B3EE1-1E7B-4C4B-9F49-A9E1DBB80B68 @default.
- Q37376149 P921 Q37376149-B1F7473E-C6EB-4DAB-BC88-B4B53C388B72 @default.
- Q37376149 P921 Q37376149-ED193A3F-BD51-48B5-A9E5-2B9E230EFEBB @default.
- Q37376149 P356 S12032-008-9148-X @default.
- Q37376149 P698 19165638 @default.
- Q37376149 P1433 Q2152666 @default.
- Q37376149 P1476 "Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy" @default.
- Q37376149 P2093 "Michael B Atkins" @default.
- Q37376149 P2860 Q28208220 @default.
- Q37376149 P2860 Q28282757 @default.
- Q37376149 P2860 Q29618031 @default.
- Q37376149 P2860 Q29618608 @default.
- Q37376149 P2860 Q34536176 @default.
- Q37376149 P2860 Q34553839 @default.
- Q37376149 P2860 Q34586436 @default.
- Q37376149 P2860 Q34617659 @default.
- Q37376149 P2860 Q40382856 @default.
- Q37376149 P2860 Q41614100 @default.
- Q37376149 P2860 Q43843476 @default.
- Q37376149 P2860 Q47376009 @default.
- Q37376149 P2860 Q53675646 @default.
- Q37376149 P2888 s12032-008-9148-x @default.
- Q37376149 P304 "18-22" @default.
- Q37376149 P31 Q13442814 @default.
- Q37376149 P31 Q7318358 @default.
- Q37376149 P356 "10.1007/S12032-008-9148-X" @default.
- Q37376149 P478 "26 Suppl 1" @default.
- Q37376149 P577 "2009-01-23T00:00:00Z" @default.
- Q37376149 P698 "19165638" @default.
- Q37376149 P921 Q1164529 @default.
- Q37376149 P921 Q1427096 @default.
- Q37376149 P921 Q19000948 @default.